Cardiac autonomic neuropathy (CAN) is a frequent chronic complication of diabetes mellitus
with potentially life-threatening outcomes. CAN is caused by the impairment of the …

Diabetic mellitus (DM) is a common degenerative chronic metabolic disease often
accompanied by severe cardiovascular complications (DCCs) as major causes of death in …

Impaired cardiac microvascular function contributes to cardiovascular complications in
diabetes. Glucagon-like peptide-1 (GLP-1) exhibits potential cardioprotective properties in …

Diabetic cardiomyopathy (DCM), an independent coronary heart disease that develops in
diabetic individuals, is characterized by changes in the myocardial structure and function …

Diabetics have higher morbidity and mortality in cardiovascular disease (CVD). A variety of
antidiabetic agents are available for clinical choice. Cardiovascular (CV) safety assessment …

Mitochondrial injury and defective autophagy are common in diabetic cardiomyopathy.
Recent evidence supports benefits of glucagon‐like peptide‐1 (GLP‐1) agonists exendin‐4 …

Myocardial ischemia/reperfusion (MI/R) leads to oxidative stress, which may in turn lead to
myocardial injury. In the present study, we investigated the effects of exenatide, a glucagon …

The purpose of this study is to investigate the effects and the underlying mechanisms of
sitagliptin pretreatment on myocardial injury and cardiac function in myocardial …

Cardiovascular disease (CVD) is one of the most severe diseases in clinics. Fibroblast
growth factor 21 (FGF21) is regarded as an important metabolic regulator playing a …

Accumulating evidence suggests that glucagon-like peptide-1 (GLP-1) and its analogues
exert cardioprotective effects via modulating cardiomyocyte metabolism. Mitochondria play a …